8-K Announcements
6Material company update
Mar 4, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Feb 23, 2026·SEC
Ventyx Biosciences, Inc.(VTYX)Earnings, Financials & Key Ratios
VTYX•NASDAQ
$14.00
Price updated May 1, 2026
AboutVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.Show more
- Revenue$0
- EBITDA-$147M+29.0%
- Net Income-$135M+30.0%
- EPS (Diluted)-1.97+40.3%
- ROE-54.27%+15.9%
VTYX Price & Volume
Ventyx Biosciences, Inc. (VTYX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pivot Fails To Stem Cash Burn
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical liquidity and funding
Key Thesis Takeaways
- Ventyx Biosciences faces a precarious financial outlook as it navigates a post-psoriasis pivot with limited liquidity.
- While management has successfully reduced quarterly R&D expenditures from $49.8M in 2023Q3 to $17.7M in 2025Q3, the company remains entirely dependent on its intangible clinical pipeline.
- Investors should monitor the critical cash runway, as the current $32.0M cash balance may necessitate immediate, highly dilutive financing to sustain operations.
Verdict Logic
the company's liquidity position is critically strained with only $32.0M in cash remaining as of 2025Q3, suggesting an imminent risk of significant shareholder dilution to fund ongoing clinical development.
VTYX Growth Metrics
Ventyx Biosciences, Inc. (VTYX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM30.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.44%
Return on Capital
10 Years-52.33%
5 Years-52.33%
3 Years-53.67%
Last Year-57.18%
VTYX Recent Earnings
Ventyx Biosciences, Inc. (VTYX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q4 2025Latest
Nov 6, 2025Metric
Actual
Est
EPS
$0.32+28.9%
$0.45
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.38+15.6%
$0.45
Rev
—
—
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$0.39+18.8%
$0.48
Rev
—
—
Q1 2025
Feb 27, 2025Metric
Actual
Est
EPS
$0.41+24.1%
$0.54
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 6, 2025 | $0.32vs $0.45+28.9% | — |
| Q3 2025 | Aug 7, 2025 | $0.38vs $0.45+15.6% | — |
| Q2 2025 | May 8, 2025 | $0.39vs $0.48+18.8% | — |
| Q1 2025 | Feb 27, 2025 | $0.41vs $0.54+24.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Ventyx Biosciences, Inc. (VTYX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.00 | $998.72M | -7.11 | — | — | -54.27% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $60.89 | $2.62B | -38.30 | 146.71% | -9.02% | -14.19% | — |
Compare VTYX vs Peers
Ventyx Biosciences, Inc. (VTYX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VTYX SEC Filings & Documents
Ventyx Biosciences, Inc. (VTYX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VTYX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VTYX Frequently Asked Questions
Ventyx Biosciences, Inc. (VTYX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is VTYX profitable?
Ventyx Biosciences, Inc. (VTYX) reported a net loss of $106.6M for fiscal year 2024.
Dividend & Returns
What is VTYX's return on equity?
Ventyx Biosciences, Inc. (VTYX) has a return on equity (ROE) of -54.3%. Negative ROE indicates the company is unprofitable.
What is Ventyx Biosciences, Inc.'s free cash flow?
Ventyx Biosciences, Inc. (VTYX) had negative free cash flow of $87.9M in fiscal year 2024, likely due to heavy capital investments.